[2] [2] SI Y, WANG C, GUO Y,et al. Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the Chinese mainland: a systematic review and meta-analysis [J]. Iran J Public Health, 2019, 48(7): 1203-1214.

[3] [3] AI Y, XU R, LIU L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis [J]. Diabetol Metab Syndr, 2021, 13(1): 93.

[4] [4] ZHANG N, ZHANG Z K, YU Y, et al. Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy [J]. Front Cell Dev Biol, 2020, 8:325.

[5] [5] MIEDANY YE, GAAFARY ME, TOTH M,et al. Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? [J]. Clin Rheumatol, 2021,40(10): 4225-4232.

[6] [6] Organization WH. Definition, diagnosis and classification of diabetes mellitus and its complications report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus [EB/OL]. Geneva : World Health Organization,1999(2018-08-19) [2025-01-12]. http://www.who.int/iris/handle/10665/66040.

[7] [7] CRUZ-JENTOFT AJ, BAHAT G, BAUER J, et al. Sarcopenia: revised European consensus on definition and diagnosis [J]. Age Ageing, 2019, 48 (4): 601.

[9] [9] Federation ID. IDF Diabetes Atlas, 10th Edition [M]. Brussels: International Diabetes Federation, 2021: 156-159.

[10] [10] JANSSEN I, HEYMSFIELD SB, WANG ZM, et al. Skeletal muscle mass and distribution in 468 men and women aged 18—88 yr[J]. J Appl Physiol (1985), 2000, 89(1): 81-88.

[11] [11] STUDENSKI S, PERERA S, PATEL K, et al. Gait speed and survival in older adults [J]. J Am Med Assoc, 2011, 305 (1):50-58.

[12] [12] TAKAYANAGI H. RANKL as the master regulator of osteoclast differentiation [J]. J Bone Miner Metab, 2021,39(1): 13-18.

[13] [13] ONO T, HAYASHI M, SASAKI F,et al. RANKL biology: bone metabolism, the immune system, and beyond[J]. Inflamm Regen, 2020, 40: 2.

[14] [14] GOSTAGE J, KOSTENUIK P, GOLJANEK-WHYSALL K,et al. Extra-osseous roles of the RANK-RANKL-OPG axis with a focus on skeletal muscle [J]. Curr Osteoporos Rep,2024, 22 (6): 632-650.

[15] [15] MARCADET L, BOUREDJI Z, ARGAW A,et al. The roles of RANK/RANKL/OPG in cardiac, skeletal, and smooth muscles in health and disease [J]. Front Cell Dev Biol, 2022,10: 903657.

[16] [16] BOUREDJI Z, HAMOUDI D, MARCADET L,et al. Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair [J]. Mol Ther Methods Clin Dev, 2021, 21: 559-573.

[18] [18] KERR DA, BRCIC I, DIAZ-PEREZ JA,et al. Immunohistochemical characterization of giant cell tumor of bone treated with denosumab: support for osteoblastic differentiation [J]. Am J Surg Pathol, 2021, 45(1): 93-100.

[19] [19] HAMOUDI D, BOUREDJI Z, MARCADET L,et al. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice [J]. Hum Mol Genet, 2020, 29 (3): 483-494.

[20] [20] DUFRESNE SS, DUMONT NA, BOULANGER-PIETTE A,et al. Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles[J]. Am J Physiol Cell Physiol, 2016, 310(8): C663-C672.

[21] [21] BONNET N, BOURGOIN L, BIVER E,et al. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass [J]. J Clin Invest, 2019, 129(8):3214-3223.

[24] [24] ZHANG C, SHEN G, LI H,et al. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: a systematic review and meta analysis[J]. Spec Care Dentistry, 2024, 44(2): 530-541.